The next pandemic won’t wait. When it comes, the UK will need rapid trials, decisive regulation and fast translation of evidence into care in order to save lives. The COVID-19 Inquiry Module 4 report suggests we still have the structures in place. However, it does not guarantee we still have the people.
What worked: translating research into practice
During COVID-19, the UK delivered at extraordinary speed – world-leading trials, rapid vaccine development, and one of the fastest rollouts globally. The BMA and others have rightly highlighted the central role of general practice in achieving this mass vaccination effort, with GP-led systems providing trusted, scalable delivery at pace.
However, that success did not occur in isolation. It depended on the prior work of medical academics who generated the evidence, defined the protocols, and informed the prioritisation strategies that made such a rollout both safe and effective. The UK delivered a true ‘bench to bedside to community’ continuum – where discovery science, clinical trials, and primary care implementation operated as a single, aligned system.
The people behind the system
At the heart of the UK’s success was a highly skilled, embedded clinical academic workforce.
Within weeks, academic clinicians working in the NHS designed and delivered platform trials at scale – identifying effective treatments, ruling out ineffective ones, and shaping global practice.
This was not luck. It was decades of investment in clinical academia – people trained to bridge patient care, research and policy.
Many of the most consequential decisions – such as prioritisation strategies and vaccine dosing intervals – relied on expert interpretation of evolving evidence. Advisory bodies and regulators were able to act decisively, because they drew on experienced clinical academics able to balance uncertainty with real-world constraints.
In short: the system worked because the right people with the right skills were in place.
Why infrastructure alone is not enough
The COVID Inquiry rightly called for continued investment in research infrastructure, regulatory capability and manufacturing resilience. But infrastructure alone is insufficient.
Clinical trials do not design themselves. Adaptive platforms do not run without leadership. Regulatory agility depends on people who understand both science and system. These capabilities take decades to build.
In 10 to 15 years, we may have the same structures – but not the experience to mobilise them. The risk is slower responses, fewer insights, and greater reliance on evidence generated elsewhere.
A pipeline at risk
The medical academic workforce that underpinned the UK’s pandemic response is ageing. Many who led trials, advised government, and translated evidence into practice are now in later career stages or have already retired.
A recent Medical Schools Council report highlighted a sustained decline in medical academic numbers, with around a 5–10% reduction over the past decade and fewer than 5% of doctors pursuing an academic pathway. Three years ago, the chair of the Science and Technology Committee, Baroness Brown, described the clinical research environment in the NHS as being on a ‘dangerous precipice’.
Since then, the situation in clinical academic staffing has continued to decline. Financial disincentives, reduced protected time and rising service pressures are deterring early-career entry.
This is a structural vulnerability.
What should be done?
For the BMA and the wider profession, this is central to patient care and national preparedness. The priorities are clear – but so too is the need for reflection.
The BMA supports the urgent actions needed to reverse the decline in clinical academics. There are distinct challenges for clinical academics, the parallel workforce within HEIs (higher education institutions), where many doctors are employed. Failure for Government to provide equitable funding for pay uplifts across NHS and university-employed clinicians has contributed to widening financial disparities between purely clinical and academic career paths.
This matters. Academic careers already carry opportunity costs – longer training, delayed earnings, and less predictable progression. When pay settlements diverge, the signal to early-career doctors is clear: academia is the less viable option.
Addressing the workforce crisis therefore requires not only forward-looking policy, but acknowledgement of where current approaches may have unintentionally accelerated the decline.
The priorities now should be to:
- protect and expand clinical academic training pathways
- ensure equitable pay and funding mechanisms across NHS and HEI-employed clinicians
- remove financial penalties associated with academic careers
- guarantee protected research time in NHS roles
- support early-career clinicians into academia
- plan for succession in trial leadership and regulatory science.
The choice ahead
When clinical academia is strong and aligned with the NHS, the UK saves lives. The Inquiry confirms it.
The question is simple: will we invest in the people who will have to do it again?
David Strain is co-chair of the BMA medical academic staff committee